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Abstract
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Objective: To assess the feasibility of contrast-enhanced spectral mammography (CESM) of the breast for assessing the size of 
residual tumors after neoadjuvant chemotherapy (NAC).
Materials and Methods: In breast cancer patients who underwent NAC between 2011 and 2013, we evaluated residual tumor mea-
surements obtained with CESM and full-field digital mammography (FFDM). We determined the concordance between the methods, 
as well as their level of agreement with the pathology. Three radiologists analyzed eight CESM and FFDM measurements separately, 
considering the size of the residual tumor at its largest diameter and correlating it with that determined in the pathological analysis. 
Interobserver agreement was also evaluated.
Results: The sensitivity, specificity, positive predictive value, and negative predictive value were higher for CESM than for FFDM 
(83.33%, 100%, 100%, and 66% vs. 50%, 50%, 50%, and 25%, respectively). The CESM measurements showed a strong, consistent 
correlation with the pathological findings (correlation coefficient = 0.76–0.92; intraclass correlation coefficient = 0.692–0.886). 
The correlation between the FFDM measurements and the pathological findings was not statistically significant, with questionable 
consistency (intraclass correlation coefficient = 0.488–0.598). Agreement with the pathological findings was narrower for CESM 
measurements than for FFDM measurements. Interobserver agreement was higher for CESM than for FFDM (0.94 vs. 0.88).
Conclusion: CESM is a feasible means of evaluating residual tumor size after NAC, showing a good correlation and good agreement 
with pathological findings. For CESM measurements, the interobserver agreement was excellent.
Keywords: Mammography/methods; Breast neoplasms/diagnosis; Magnetic resonance imaging; Neoadjuvant therapy/methods.
Objetivo: Avaliar a viabilidade da utilização da mamografia espectral com meio de contraste (CESM) na avaliação do tumor residual 
em mulheres com câncer de mama submetidas a quimioterapia neoadjuvante.
Materiais e Métodos: Foi avaliada a concordância entre a mensuração do tumor residual na CESM e na mamografia digital (FFDM) 
com os dados histopatológicos de mulheres submetidas a quimioterapia neoadjuvante entre 2011 e 2013. Após as exclusões, 
três radiologistas analisaram oito CESMs e FFDMs separadamente. A maior dimensão do tumor residual foi considerada para 
comparação com os resultados histopatológicos. Concordância e correlação da CESM e FFDM com resultados histopatológicos e a 
concordância interobservador foram avaliadas.
Resultados: A CESM teve sensibilidade, especificidade e valores preditivos positivos e negativos maiores que a FFDM – 83,33%, 
100%, 100% e 66% versus 50%, 50%, 50% e 25%, respectivamente. A CESM teve correlação boa e consistente com os achados 
histopatológicos (coeficiente de correlação = 0,76–0,92; coeficiente de correlação intraclasse = 0,692–0,886). A correlação entre 
FFDM e os achados histopatológicos não foi estatisticamente significante, com consistência questionável (coeficiente de correlação 
intraclasse = 0,488–0,598). A concordância entre as dimensões do estudo histopatológico foi mais estreita com a CESM do que 
com a FFDM. A concordância interobservador foi maior na CESM (0,94) do que na FFDM (0,88).
Conclusão: A CESM é viável e pode ser utilizada para avaliação de tumor residual após quimioterapia neoadjuvante. A CESM tem 
boa correlação e concordância com o estudo histopatológico e excelente concordância interobservador.
Unitermos: Mamografia/métodos; Neoplasias de mama/diagnóstico; Ressonância magnética; Terapia neoadjuvante/métodos.
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INTRODUCTION
Neoadjuvant chemotherapy (NAC) is an established 
component of breast cancer treatment. Some advantages 
of NAC include a reduction in tumor size, early treatment 
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of micrometastatic disease, and in vivo assessment of tu-
mor response(1,2). The accurate assessment of residual 
tumor extent after NAC is critical for surgical planning. 
Overestimation of the tumor extent can lead to unneces-
sary mastectomy, whereas underestimation can increase 
the risk of positive surgical margins.
Although a complete pathological response is not 
prognostic for disease-free survival in all breast cancer sub-
types, the post-NAC extent of residual disease in the breast 
and lymph nodes is associated with patient survival(3). 
Patients with a complete pathological response have a 
lower risk of locoregional relapse and are candidates for 
less extensive locoregional treatment(4).
Physical examination, ultrasound, and mammography 
have been used in order to assess residual tumor size in 
breast cancer patients after NAC, although the accuracy 
of these techniques is not satisfactory(5–7). Magnetic reso-
nance imaging (MRI) of the breast is currently the best 
modality for monitoring tumor response and for assess-
ing residual disease after NAC because it is more accu-
rate than are mammography, ultrasound, and clinical ex-
amination(8,9). However, MRI is a time-consuming exam, 
usually lasting 30–45 min, and requires a dedicated coil, 
as well as trained readers.
Contrast-enhanced spectral mammography (CESM) 
is an imaging modality that combines contrast enhance-
ment with digital mammography. Nonionic iodinated 
contrast, which is administered intravenously, allows le-
sions to be characterized based on their enhancement. 
Each CESM exposure is composed of a low-energy image, 
similar to that obtained with full-field digital mammog-
raphy (FFDM), and a high-energy image with an X-ray 
spectrum above the k-edge of iodine (33.2 keV). The 
two images are recombined, and a subtraction image of 
the lesions is produced(10,11). Initial studies comparing 
CESM with mammography, ultrasound, and MRI show 
that CESM is better at detecting suspicious lesions than 
are mammography and mammography plus ultrasound, 
as well as having an accuracy in lesion size measurement 
similar to that of MRI(12–16).
The purpose of this study was to evaluate the feasibil-
ity of using CESM to assess residual tumor extent after 
NAC in breast cancer patients. Specific objectives were to 
evaluate the accuracy of CESM in determining residual 
tumor size, using pathology results as the gold standard, 
to compare the performance of CESM with that of FFDM 
(low-energy images only), in terms of their performance, 
and to analyze interobserver agreement.
MATERIALS AND METHODS
Patients and treatment
This was a retrospective study. The study protocol was 
approved by the local research ethics committee, and in-
formed consent was waived. The patients enrolled in this 
study were selected from among all patients undergoing 
CESM at our institution between October 2011 and March 
2013. The inclusion criteria were as follows: being fe-
male; being ≥ 18 years of age; having histologically proven 
primary breast cancer; and having received NAC as part 
of the treatment. Patients who had undergone surgical 
treatment other than lumpectomy or mastectomy were 
excluded, as were those for whom there were no results 
from the histological analysis of the surgical specimen. 
The precise regimen of NAC varied and was at the discre-
tion of medical oncologist in charge.
CESM examination
All CESM examinations were performed with a com-
mercially available FFDM system (SenoDS/SenoBright; 
GE Healthcare, Buc, France). The dual-energy technique 
was applied under the supervision of a radiologist.
Dual-energy CESM exams were performed by acquir-
ing a pair of low- and high-energy images during a single 
breast compression. Low-energy images were obtained with 
a molybdenum or rhodium target and filter, whereas high- 
energy images were acquired with a molybdenum or rho-
dium target and a copper filter. Both images were acquired 
with automatic optimization of parameters.
A 1–2 mL/kg dose of a nonionic contrast agent (iohe-
xol, 300 mg/mL) was injected intravenously with an auto-
mated injector at a flow rate of 3 mL/s. Imaging was initi-
ated 1.5–2 min after the injection and continued for 3–5 
minutes. Bilateral craniocaudal and mediolateral oblique 
views were acquired. The complete examination protocol 
has been described and explained in detail elsewhere(17).
It has been demonstrated that low-energy images are 
equivalent to FFDM, even in the presence of intravenous 
iodinated contrast(18). In this study, we use the terms FFDM 
and CESM to refer to low-energy images and recombined 
images, respectively.
Image analysis
Before the readings, a radiologist with three years of 
experience in CESM (reader 1) conducted a training ses-
sion. Training cases were provided in order to familiarize 
the other radiologists with CESM and with the reading 
protocol. The same radiologist selected the cases for this 
study, split the low-energy and recombined images, ano-
nymized them, and loaded them (separately and together) 
into a workstation.
A breast radiologist with over ten years of practice 
(reader 2) and a breast imaging fellow (reader 3) reviewed 
all studies using the same radiology workstation (Seno Ad-
vantage 2.2; GE Medical Systems, Milwaukee, WI, USA). 
Tumor laterality was the only background information 
available.
To avoid memory bias, the readings were conducted 
in two review sessions with a two-week interval between 
them. In the first session, only low-energy images were in-
cluded, whereas low-energy and recombined images were 
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included in the second review session. During the second 
session, the images were reviewed separately or together. 
Data from readers 2 and 3 were comparable to those in 
the original report submitted by reader 1.
Pathology
Specimen processing was performed at a hospital, ac-
cording to the protocols of the local institution. All patho-
logical data were extracted from the pathology reports.
Tumor size measurement
Suspicious findings were measured on low-energy 
and recombined images, in the craniocaudal and medio-
lateral oblique views. Some tumors presented as multiple 
enhancing spots, irregular masses, or ill-defined asym-
metric masses. In those cases, the measurement included 
the largest tumor diameter
For analysis purposes, the largest diameters of the 
residual tumor documented on low-energy (FFDM) and 
recombined (CESM) images were compared with that de-
termined for the pathological specimen.
Statistical analysis
The size of the residual tumor determined by pathol-
ogy was set as the “gold standard” and was compared to 
the size determined from the analysis of the low-energy 
and recombined images. The agreement between the size 
determined by pathology and that determined from the 
low-energy (FFDM) and recombined (CESM) images was 
assessed with the Bland-Altman 95% limits of agreement 
and intraclass correlation coefficient (ICC)(19). Tumor size 
based on the FFDM and CESM images was also catego-
rized as in agreement, underestimated, or overestimat-
ed, in relation to the size determined by pathology. We 
used scatter plots and Pearson’s correlation coefficients 
to explore whether the size of the residual tumor deter-
mined by pathology correlated with that determined from 
the CESM and FFDM images. Values of p < 0.05 were 
considered significant. The interobserver agreement for 
each imaging technique was calculated using the limits 
of agreement and ICC. Statistical analysis was performed 




We identified 12 lesions in 11 patients who met the 
inclusion criteria. Three patients (with a collective total 
of four lesions) were excluded because two died before 
surgery and the pathology result was not available for one. 
Therefore, the final sample comprised eight lesions in 
eight patients. The mean patient age was 46.41 ± 15.19 
years (range, 22–76 years). The mean time from CESM 
and surgery was 32.6 ± 22.4 days (range, 5–66 days).
Residual tumor size
Residual tumor size ranged from microscopic (not 
measurable) to 40 mm, with a mean size of 17 mm. The size 
of the residual tumor determined from analysis of the pa-
thology specimen is shown in Table 1, as are the sizes 
determined by all readers from the FFDM and CESM im-
ages. Scatter plots of those measurements are shown in 
Figure 1.
The pathological analysis revealed residual tumors in 
six (75%) of the eight patients evaluated. Three residual 
tumors were not visible on FFDM. Among those three 
tumors, CESM missed one, overestimated one, and un-
derestimated one (Figure 2). CESM was true negative in 
Figure 1. Scatter plot of the largest diameter of post-NAC residual breast tumors, as determined by pathology, from FFDM images, and from CESM images.
Table 1—Residual breast tumor size determined by pathology, from CESM im-
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both of the patients in whom the pathological analysis 
failed to identify a residual tumor, CESM also revealed no 
residual tumor at histopathology, whereas, in one patient, 
a focal asymmetry on FFDM was interpreted as a residual 
tumor by all readers.
One patient also had a fibroadenoma (Figure 3). On 
the basis of the FFDM images, all of the readers incor-
rectly held it as suspicious and concluded that the index 
tumor, which was located in the same breast, had been 
overrun. On CESM, the index tumor showed mild en-
hancement and the fibroadenoma showed none.
The sensitivity and specificity of CESM for detect-
ing residual tumors were 83.33% and 100%, respectively, 
compared with only 50% (for both) for FFDM. A positive 
CESM examination was predictive of a residual tumor in 
100% of the cases, twice as many as did a positive FFDM 
examination, whereas a negative CESM result predicted 
the absence of a residual tumor in 66%, compared with 
25% for a negative FFDM result.
Among all readers, the ICC between the size of the re-
sidual tumor determined by imaging and that determined 
by pathology was higher for CESM than for FFDM. The 
LoA was also better  for CESM than for FFDM, as shown 
in Table 2 and Figure 4.
Residual tumor size was underestimated by FFDM 
and CESM in 50% and 37.5% of the cases, respectively, 
Figure 2. Residual (2.2-cm) tumor in a 23-year-old woman. FFDM (A) was negative, whereas CESM (B) overestimated the tumor size.
BA
Figure 3. Residual (2.2-cm) tumor in a 45-year-old woman. On FFDM (A), all readers mistook a fibroadenoma for the tumor (arrow). On CESM (B), there was het-
erogeneous enhancement consistent with a residual tumor (asterisk).
A B
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overestimated by both in 37.5%, and correctly assessed in 
12.5% and 25%, respectively.
There was a perfect agreement among readers re-
garding the presence or absence of residual tumor based 
on both FFDM and CESM (Table 1). The interobserver 
agreement was very good for both methods, although it 
was higher for CESM (Table 2).
DISCUSSION
Recent studies in the radiology literature of Brazil have 
addressed the importance of imaging in the management 
of breast cancer(20–27). Previous studies had corroborated 
the ability of CESM to detect primary breast tumors and 
demonstrated that its accuracy in preoperative tumor stag-
ing with lesion size measurement is comparable to that 
Figure 4. Bland–Altman analysis of the residual tumor size determined by pathology in comparison with that determined from the CESM and FFDM images, by all 
three readers.
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of MRI. In this feasibility study, we assessed the diagnos-
tic performance of CESM in the detection and size deter-
mination of residual tumors after NAC in breast cancer 
patients.
Our findings make it clear that CESM is a feasible 
means of detecting residual tumors after NAC. In com-
parison with FFDM, CESM increased the sensitivity 
and specificity of residual tumor detection from 50% to 
83.33% and from 50% to 100%, respectively. On post-
NAC FFDM images, residual tumors were missed in 
three patients (37.5%), compared with only one (12.5%) 
on post-NAC CESM images. Our data also suggest that a 
positive CESM indicates the presence of residual tumor 
after NAC (positive predictive value, 100%).
Previous studies have demonstrated the greater ac-
curacy of CESM in breast tumor measurement in com-
parison with MRI(13,15), ultrasound(16), and FFDM(12). In 
the present study, we were able to show that the accuracy 
of CESM in residual tumor size determination was better 
than was that of FFDM, and both methods showed good 
agreement with the pathological findings (ICC = 0.692–
0.886 and 0.488–0.598, respectively), although the cor-
relation was significant only for CESM. The residual tu-
mor size was overestimated less often by CESM than by 
FFDM. That might be especially meaningful in order to 
avoid unnecessary mastectomies and reduce the extent of 
breast conservation surgery.
Although interobserver agreement was very good 
for CESM and FFDM, it was slightly better for CESM. 
There was perfect agreement among readers regarding 
the presence or absence of residual tumors as determined 
by FFDM and CESM. The use of CESM increased the di-
agnostic performance of all readers, as was also reported 
by Dromain et al.(28) in a study with six readers. Cheung 
et al.(29) found that, among four blinded readers (radiolo-
gists) who scored lesions in terms of the probability of ma-
lignancy, interobserver agreement was significantly higher 
for CESM than for FFDM (0.62 vs. 0.38), whereas the 
difference between the two methods was smaller in the 
present study (0.94 vs. 0.88). Although this discrepancy 
is most likely attributable to a difference in sample size, 
it could also be because, in our study, the correlation was 
made on the basis of measurements, rather than scores, 
which are less subjective.
The present study has certain limitations, chief among 
which is the small size of the sample. The small sample 
size precluded an analysis of diverse cancer types and the 
collection of data regarding the influence of molecular 
subtypes. In addition, because CESM was not performed 
before or during NAC, we were unable to predict the re-
sponse or estimate tumor size reduction. Readers were not 
totally blinded, because the laterality of the tumor was 
known to them. We were also unable to perform an analy-
sis of the impact of CESM on surgical decision-making.
CONCLUSION
Our results confirm that CESM is a feasible, easily 
performed method for evaluating residual tumor size after 
NAC. CESM correlates well and shows good agreement 
with the pathology, as well as showing good interobserver 
agreement. Therefore, our findings might be used as refer-
ence data for future prospective studies designed to eval-
uate the impact of CESM on surgical decision-making.
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